{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:15:44Z","timestamp":1791231344327,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41390-020-1037-9","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T02:55:10Z","timestamp":1595386510000},"page":"1268-1277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The bioavailability and maturing clearance of doxapram in preterm infants"],"prefix":"10.1038","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-594X","authenticated-orcid":false,"given":"Robert B.","family":"Flint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinno H. P.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Andriessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian D.","family":"Liem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter L. J.","family":"Degraeuwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin K. M.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline G. J.","family":"Engbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald de","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherijne A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"V\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DINO Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"V\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G. J.","family":"Engbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Andriessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L. J.","family":"Degraeuwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. D.","family":"Liem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H. P.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. K. M.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Burggraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Allegaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tibboel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"1037_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jama.2015.8841","volume":"314","author":"CF Poets","year":"2015","unstructured":"Poets, C. F. et al. Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants. JAMA 314, 595\u2013603 (2015).","journal-title":"JAMA"},{"key":"1037_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/NPM-171686","volume":"10","author":"T Sawyer","year":"2017","unstructured":"Sawyer, T. et al. Improving neonatal intubation safety: a journey of a thousand miles. J. Neonatal Perinat. Med. 10, 125\u2013131 (2017).","journal-title":"J. Neonatal Perinat. Med."},{"key":"1037_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000448985","volume":"111","author":"DG Sweet","year":"2017","unstructured":"Sweet, D. G. et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome\u20142016 update. Neonatology 111, 107\u2013125 (2017).","journal-title":"Neonatology"},{"key":"1037_CR4","doi-asserted-by":"publisher","first-page":"F352","DOI":"10.1136\/archdischild-2015-310228","volume":"101","author":"SU Morton","year":"2016","unstructured":"Morton, S. U. & Smith, V. C. Treatment options for apnoea of prematurity. Arch. Dis. Child Fetal Neonatal Ed. 101, F352\u2013F356 (2016).","journal-title":"Arch. Dis. Child Fetal Neonatal Ed."},{"key":"1037_CR5","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa054065","volume":"354","author":"B Schmidt","year":"2006","unstructured":"Schmidt, B. et al. Caffeine therapy for apnea of prematurity. N. Engl. J. Med. 354, 2112\u20132121 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1037_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2011.2024","volume":"307","author":"B Schmidt","year":"2012","unstructured":"Schmidt, B. et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 307, 275\u2013282 (2012).","journal-title":"JAMA"},{"key":"1037_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/apa.13761","volume":"106","author":"R Flint","year":"2017","unstructured":"Flint, R. et al. Retrospective study shows that doxapram therapy avoided the need for endotracheal intubation in most premature neonates. Acta Paediatr. 106, 733\u2013739 (2017).","journal-title":"Acta Paediatr."},{"key":"1037_CR8","doi-asserted-by":"publisher","first-page":"251047","DOI":"10.1155\/2013\/251047","volume":"2013","author":"SA Prins","year":"2013","unstructured":"Prins, S. A. et al. Doxapram use for apnoea of prematurity in neonatal intensive care. Int. J. Pediatr. 2013, 251047 (2013).","journal-title":"Int. J. Pediatr."},{"key":"1037_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S0022-3476(84)80568-5","volume":"104","author":"G Alpan","year":"1984","unstructured":"Alpan, G. et al. Clinical and laboratory observations\u2014doxapram in the treatment of idiopathic apnea of prematurity unresponsive to aminophylline. J. Pediatr. 104, 634\u2013637 (1984).","journal-title":"J. Pediatr."},{"key":"1037_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1542\/peds.75.4.709","volume":"75","author":"F Eyal","year":"1985","unstructured":"Eyal, F. et al. Aminophylline versus doxapram in idiopathic apnea of prematurity\u2014a double-blind controlled-study. Pediatrics 75, 709\u2013713 (1985).","journal-title":"Pediatrics"},{"key":"1037_CR11","unstructured":"Dopram 2\u2009mg\/ml-actualisatie-SPC-08-2010. https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h07309_smpc.pdf. Revised 07-03-2012."},{"key":"1037_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1542\/peds.80.1.22","volume":"80","author":"KJ Barrington","year":"1987","unstructured":"Barrington, K. J. et al. Dose\u2013response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. Pediatrics 80, 22\u201327 (1987).","journal-title":"Pediatrics"},{"key":"1037_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000448941","volume":"111","author":"RJ Vliegenthart","year":"2016","unstructured":"Vliegenthart, R. J., Ten Hove, C. H., Onland, W. & van Kaam, A. H. Doxapram treatment for apnea of prematurity: a systematic review. Neonatology 111, 162\u2013171 (2016).","journal-title":"Neonatology"},{"key":"1037_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000014160","volume":"76","author":"CF Poets","year":"1999","unstructured":"Poets, C. F., Darraj, S. & Bohnhorst, B. Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. Biol. Neonate 76, 207\u2013213 (1999).","journal-title":"Biol. Neonate"},{"key":"1037_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0006-8993(91)91386-F","volume":"568","author":"C Peers","year":"1991","unstructured":"Peers, C. Effects of doxapram on ionic currents recorded in isolated type-i cells of the neonatal rat carotid-body. Brain Res. 568, 116\u2013122 (1991).","journal-title":"Brain Res."},{"key":"1037_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0022-3476(86)80786-7","volume":"108","author":"KJ Barrington","year":"1986","unstructured":"Barrington, K. J., Finer, N. N., Peters, K. L. & Barton, J. Physiologic effects of doxapram in idiopathic apnea of prematurity. J. Pediatr. 108, 124\u2013129 (1986).","journal-title":"J. Pediatr."},{"key":"1037_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/clpt.1991.101","volume":"50","author":"A Bairam","year":"1991","unstructured":"Bairam, A. et al. Doxapram metabolism in human fetal hepatic organ culture. Clin. Pharmacol. Ther. 50, 32\u201338 (1991).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1037_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00431-014-2416-1","volume":"174","author":"Y Ogawa","year":"2015","unstructured":"Ogawa, Y. et al. Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur. J. Pediatr. 174, 509\u2013518 (2015).","journal-title":"Eur. J. Pediatr."},{"key":"1037_CR19","first-page":"142","volume":"28","author":"A Bairam","year":"1990","unstructured":"Bairam, A. et al. Pharmacodynamic effects and pharmacokinetic profiles of keto-doxapram and doxapram in newborn lambs. Pediatr. Res. 28, 142\u2013146 (1990).","journal-title":"Pediatr. Res."},{"key":"1037_CR20","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ejps.2017.05.022","volume":"109S","author":"EHJ Krekels","year":"2017","unstructured":"Krekels, E. H. J. et al. Evidence-based drug treatment for special patient populations through model-based approaches. Eur. J. Pharm. Sci. 109S, S22\u2013S26 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"1037_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/17512433.2016.1198256","volume":"9","author":"JM Brussee","year":"2016","unstructured":"Brussee, J. M. et al. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev. Clin. Pharmacol. 9, 1235\u20131244 (2016).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"Suppl. 1","key":"1037_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","volume":"67","author":"RF De Cock","year":"2011","unstructured":"De Cock, R. F. et al. The role of population PK-PD modelling in paediatric clinical research. Eur. J. Clin. Pharmacol. 67(Suppl. 1), 5\u201316 (2011).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"1037_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/00007691-199910000-00011","volume":"21","author":"F Barbe","year":"1999","unstructured":"Barbe, F. et al. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther. Drug Monit. 21, 547\u2013552 (1999).","journal-title":"Ther. Drug Monit."},{"key":"1037_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000457699","volume":"11","author":"F Jamali","year":"1988","unstructured":"Jamali, F. et al. Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. Dev. Pharm. Ther. 11, 253\u2013257 (1988).","journal-title":"Dev. Pharm. Ther."},{"key":"1037_CR25","doi-asserted-by":"publisher","first-page":"e4290","DOI":"10.1002\/bmc.4290","volume":"32","author":"RB Flint","year":"2018","unstructured":"Flint, R. B., Bahmany, S., van der Nagel, B. C. H. & Koch, B. C. P. Simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto-doxapram in plasma using liquid chromatography\u2014tandem mass spectrometry. Biomed. Chromatogr. 32, e4290 (2018).","journal-title":"Biomed. Chromatogr."},{"key":"1037_CR26","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer, R. J., Karlsson, M. O. & Hooker, A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet. Syst. Pharmacol. 2, e50 (2013).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1037_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne, A. G., Bergstrand, M., Harling, K. & Karlsson, M. O. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J. Pharmacokinet. Pharmacodyn. 43, 583\u2013596 (2016).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"1037_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom, L., Pihlgren, P. & Jonsson, E. N. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Prog. Biomed. 79, 241\u2013257 (2005).","journal-title":"Comput. Methods Prog. Biomed."},{"key":"1037_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets, E., Brendel, K. & Mentre, F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput. Methods Prog. Biomed. 90, 154\u2013166 (2008).","journal-title":"Comput. Methods Prog. Biomed."},{"key":"1037_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1590\/S0100-879X2003000600012","volume":"36","author":"LM Anchieta","year":"2003","unstructured":"Anchieta, L. M., Xavier, C. C., Colosimo, E. A. & Souza, M. F. Weight of preterm newborns during the first twelve weeks of life. Braz. J. Med. Biol. Res. 36, 761\u2013770 (2003).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"1037_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40272-016-0192-2","volume":"18","author":"E Greze","year":"2016","unstructured":"Greze, E. et al. Doxapram dosing for apnea of prematurity based on postmenstrual age and gender: a Randomized Controlled Trial. Paediatr. Drugs 18, 443\u2013449 (2016).","journal-title":"Paediatr. Drugs"},{"key":"1037_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1034\/j.1600-0773.2001.088001003.x","volume":"88","author":"PJ Gow","year":"2001","unstructured":"Gow, P. J. et al. Neonatal hepatic drug elimination. Pharmacol. Toxicol. 88, 3\u201315 (2001).","journal-title":"Pharmacol. Toxicol."},{"key":"1037_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.sempedsurg.2013.10.006","volume":"22","author":"J Grijalva","year":"2013","unstructured":"Grijalva, J. & Vakili, K. Neonatal liver physiology. Semin. Pediatr. Surg. 22, 185\u2013189 (2013).","journal-title":"Semin. Pediatr. Surg."},{"key":"1037_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bcp.13459","volume":"84","author":"JM Brussee","year":"2018","unstructured":"Brussee, J. M. et al. Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. Br. J. Clin. Pharmacol. 84, 358\u2013368 (2018).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1037_CR35","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/jcph.1429","volume":"59","author":"S Voller","year":"2019","unstructured":"Voller, S. et al. Recently registered midazolam doses for preterm neonates do not lead to equal exposure: a population pharmacokinetic model. J. Clin. Pharmacol. 59, 1300\u20131308 (2019).","journal-title":"J. Clin. Pharmacol."},{"key":"1037_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2125.1979.tb00901.x","volume":"7","author":"RH Robson","year":"1979","unstructured":"Robson, R. H. & Prescott, L. F. A pharmacokinetic study of doxapram in patients and volunteers. Br. J. Clin. Pharmacol. 7, 81\u201387 (1979).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1037_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/psp4.12295","volume":"7","author":"JM Brussee","year":"2018","unstructured":"Brussee, J. M. et al. First-pass CYP3A-mediated metabolism of midazolam in the gut wall and liver in preterm neonates. CPT Pharmacomet. Syst. Pharmacol. 7, 374\u2013383 (2018).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1037_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.resp.2005.04.009","volume":"149","author":"JL Carroll","year":"2005","unstructured":"Carroll, J. L. & Kim, I. Postnatal development of carotid body glomus cell O2 sensitivity. Respir. Physiol. Neurobiol. 149, 201\u2013215 (2005).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"1037_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.resp.2012.05.026","volume":"185","author":"MT Wong-Riley","year":"2013","unstructured":"Wong-Riley, M. T., Liu, Q. & Gao, X. P. Peripheral-central chemoreceptor interaction and the significance of a critical period in the development of respiratory control. Respir. Physiol. Neurobiol. 185, 156\u2013169 (2013).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"1037_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fphar.2020.00665","volume":"11","author":"JA Poppe","year":"2020","unstructured":"Poppe, J. A. et al. Precision dosing of doxapram in preterm infants using continuous pharmacodynamic data and model-based pharmacokinetics: an illustrative case series. Front. Pharmacol. 11, 665 (2020).","journal-title":"Front. Pharmacol."},{"key":"1037_CR41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0009-9236(01)95877-1","volume":"70","author":"C Maillard","year":"2001","unstructured":"Maillard, C. et al. QT interval lengthening in premature infants treated with doxapram. Clin. Pharm. Ther. 70, 540\u2013545 (2001).","journal-title":"Clin. Pharm. Ther."},{"key":"1037_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0022-3476(98)70197-0","volume":"133","author":"GS De Villiers","year":"1998","unstructured":"De Villiers, G. S., Walele, A., Van der Merwe, P. L. & Kalis, N. N. Second-degree atrioventricular heart block after doxapram administration. J. Pediatr. 133, 149\u2013150 (1998).","journal-title":"J. Pediatr."},{"key":"1037_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000243342","volume":"59","author":"J Tay-Uyboco","year":"1991","unstructured":"Tay-Uyboco, J. et al. Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. Biol. Neonate 59, 190\u2013200 (1991).","journal-title":"Biol. Neonate"},{"key":"1037_CR44","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/apa.12681","volume":"103","author":"C Czaba-Hnizdo","year":"2014","unstructured":"Czaba-Hnizdo, C. et al. Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants. Acta Paediatr. 103, 922\u2013927 (2014).","journal-title":"Acta Paediatr."},{"key":"1037_CR45","doi-asserted-by":"publisher","first-page":"F416","DOI":"10.1136\/archdischild-2012-303089","volume":"98","author":"C Fischer","year":"2013","unstructured":"Fischer, C., Ferdynus, C., Gouyon, J. B. & Semama, D. S. Doxapram and hypokalaemia in very preterm infants. Arch. Dis. Child Fetal Neonatal Ed. 98, F416\u2013F418 (2013).","journal-title":"Arch. Dis. Child Fetal Neonatal Ed."},{"key":"1037_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41372-018-0087-x","volume":"38","author":"T Shimokaze","year":"2018","unstructured":"Shimokaze, T., Toyoshima, K., Shibasaki, J. & Itani, Y. Blood potassium and urine aldosterone after doxapram therapy for preterm infants. J. Perinatol. 38, 702\u2013707 (2018).","journal-title":"J. Perinatol."},{"key":"1037_CR47","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.2174\/1381612823666170918121556","volume":"23","author":"RB Flint","year":"2017","unstructured":"Flint, R. B. et al. Big data analyses for continuous evaluation of pharmacotherapy: a proof of principle with doxapram in preterm infants. Curr. Pharm. Des. 23, 5919\u20135927 (2017).","journal-title":"Curr. Pharm. Des."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-1037-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-1037-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-1037-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:04:20Z","timestamp":1757941460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-1037-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1038\/s41390-020-1037-9","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"14 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Erasmus MC ethics review board approved the protocol and written informed consent from parents\/legal guardians was obtained prior to study initiation (MEC-2014-067).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}